On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
- Sakigake Status Withdrawn for Aducanumab: MHLW
September 20, 2019
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- Doctor, Payer Reps Stress Need for More Education about Biosimilars Before Introducing Premium for Their Use: Chuikyo
September 19, 2019
- MHLW Panel Backs Inclusion of Rotavirus Vaccines to Public Immunization Program
September 17, 2019
- Orphan Status Granted to Satralizumab, 2 Other Drugs
September 17, 2019
- Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
- Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
- Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
- Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application
September 12, 2019
- 9 Topics Presented towards 2020 Pricing Reform; Industry Hearing Slated for November-December: Chuikyo
September 12, 2019
- Katsunobu Kato Makes Comeback as Health Minister
September 11, 2019
- MHLW Vows to Redouble Efforts to Prevent Future Information Leaks
September 11, 2019
- RWD Use in Regulatory Submissions Could Start with Rare Diseases: PMDA Chief
September 10, 2019
- MOF Budget Examiner Sounds Alarm on “Protected” Market, Prods Speedy Transformation
September 10, 2019
- MHLW Eyes More Convenient Sakigake Scheme with Legislation, Criteria Won't Change: Official
September 10, 2019
- Evenity Ordered to Warn of CV Event Risks in Revised Label
September 9, 2019
- MHLW to Launch 5th Round of Sakigake Invitations on Oct. 1
September 9, 2019
- MHLW Loathe to Disclose Probe Documents on Clinical Research Bill Leak
September 6, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…